Hims & Hers Canada has introduced generic semaglutide, a treatment that could revolutionize access to obesity medicine for Canadians. As an obesity medicine specialist and Chief Medical Officer, I find this moment both exciting and transformative: more choice, lower costs, and a shift toward holistic care that prioritizes whole patient health. Nearly two-thirds of Canadian adults struggle with overweight or obesity, underscoring the urgent need for affordable, effective solutions. Health Canada’s authorization of semaglutide marks a turning point, not just for customers but for the country’s healthcare landscape. When generics enter the GLP-1 space, prices fall across the board, offering broader accessibility. This change benefits everyone, regardless of location, and aligns with growing public demand for personalized care plans. However, while medication is a tool, it’s only one piece of a comprehensive care strategy. Through Hims & Hers, patients can begin with a personalized clinical assessment, starting at CAD $149/month, supported by integrated care teams that provide nutrition, movement, and sleep guidance. These plans are designed to promote long-term health habits, reflecting our commitment to patient-centered care. I joined Hims & Hers as a leader in building programs grounded in clinical rigor and understanding the lived experience of Canadians navigating healthcare systems. Our approach emphasizes that obesity is a chronic, complex condition, not a failure of willpower. Every decision we make ensures affordability, quality, and sustainability. By partnering with licensed providers who understand the local context, we empower individuals to take control of their health. In doing so, Hims & Hers is committed to delivering tools, providers, and support that truly reflect what Canadians deserve—access to care that supports lasting wellness.
